Nitrostat

See also: Generic Nitro-Dur, Generic Nitrolingual Pumpspray, Generic NitroMist

Nitrostat is a brand name of nitroglycerin, approved by the FDA in the following formulation(s):

NITROSTAT (nitroglycerin - tablet; sublingual)

• 
  Manufacturer: PFIZER PHARMS
  
  Approval date: May 1, 2000
  
  Strength(s): 0.3MG, 0.4MG, 0.6MG ^[RLD]

Has a generic version of Nitrostat been approved?

No. There is currently no therapeutically equivalent version of Nitrostat available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nitrostat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compressed nitroglycerin tablet and its method of manufacture
  Patent 6,500,456
  Issued: December 31, 2002
  Inventor(s): Roberto L.; Capella
  Assignee(s): Warner-Lambert Company
  The present invention is directed to a stable nitroglycerin containing pharmaceutical composition, preferably a tablet which is prepared by direct compression technology. The formulation closely replicates the properties of nitroglycerin molded sublingual tablets (e.g. adequate disintegration and sublingual absorption), while reducing the problems experienced with compressed tablets (e.g. friability and weight variations). The stable tablets are characterized by a decreased migration of nitroglycerin, decreased potency loss, excellent content uniformity when stored. The preferred combination of components are: nitroglycerin/lactose dilution, hydrous lactose, glyceril monostearate, fumed silica, pregelantinized starch and calcium stearate. The preferred process employs direct compression technology to yield composition showing adequate disintegration, bioavailability and improved stability.
  
  Patent expiration dates:
  
  
  • September 16, 2018
    
  
  

See also...

• Nitrostat Consumer Information (Wolters Kluwer)
• Nitrostat oral/sublingual Consumer Information (Cerner Multum)
• Nitrostat Advanced Consumer Information (Micromedex)
• Nitroglycerin Consumer Information (Wolters Kluwer)
• Nitroglycerin Aerosol Consumer Information (Wolters Kluwer)
• Nitroglycerin Controlled-Release Capsules Consumer Information (Wolters Kluwer)
• Nitroglycerin Ointment Consumer Information (Wolters Kluwer)
• Nitroglycerin Patch Consumer Information (Wolters Kluwer)
• Nitroglycerin Spray Consumer Information (Wolters Kluwer)
• Nitroglycerin Tablets Consumer Information (Wolters Kluwer)
• Nitroglycerin oral/sublingual Consumer Information (Cerner Multum)
• Nitroglycerin topical Consumer Information (Cerner Multum)
• Nitroglycerin transdermal Consumer Information (Cerner Multum)
• Gen-Nitro Advanced Consumer Information (Micromedex)
• Nitrotab Advanced Consumer Information (Micromedex)
• Trinipatch 0.2 Advanced Consumer Information (Micromedex)
• Trinipatch 0.4 Advanced Consumer Information (Micromedex)
• Trinipatch 0.6 Advanced Consumer Information (Micromedex)
• Nitroglycerin Intravenous Advanced Consumer Information (Micromedex)
• Nitroglycerin Oral, Sublingual Advanced Consumer Information (Micromedex)
• Nitroglycerin Transdermal Advanced Consumer Information (Micromedex)
• Nitroglycerin AHFS DI Monographs (ASHP)